tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shanghai Bio-heart Completes H Share Repurchase and Capital Reduction

Story Highlights
Shanghai Bio-heart Completes H Share Repurchase and Capital Reduction

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an announcement.

Shanghai Bio-heart Biological Technology Co., Ltd. has completed the repurchase and cancellation of H shares as part of its 2022 H Share Incentive Scheme, resulting in a reduction of its registered share capital from RMB243,937,000 to RMB243,417,100. This move, representing approximately 0.21% of the company’s total issued share capital, does not impact the company’s public float as per the Listing Rules, indicating a strategic adjustment in its shareholding structure.

More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H

Shanghai Bio-heart Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biotechnology industry. The company is involved in the development and provision of biological technology solutions, with a market focus on innovative health technologies.

Average Trading Volume: 960,904

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.74B

For a thorough assessment of 2185 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1